Provectus Biopharmaceuticals, Inc. (PVCT)

Market Cap	29.04M -15.2%
Revenue (ttm)	336.11K -45.5%
Net Income	-5.43M
EPS	-0.01
Shares Out	420.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,200
Average Volume	191,031
Open	0.0700
Previous Close	0.0700
Day's Range	0.0690 - 0.0700
52-Week Range	0.0380 - 0.1050
Beta	0.80
RSI	66.00
Earnings Date	May 19, 2026

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company’s lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: PVCT

Financial Performance

In 2025, PVCT's revenue was $336,108, a decrease of -45.54% compared to the previous year's $617,140. Losses were -$5.43 million, 14.8% more than in 2024.